<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355081</url>
  </required_header>
  <id_info>
    <org_study_id>LuAA21004/CCT-003</org_study_id>
    <secondary_id>U1111-1120-9277</secondary_id>
    <secondary_id>JapicCTI-111492</secondary_id>
    <nct_id>NCT01355081</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety and tolerability of 8-week
      treatment with Vortioxetine (Lu AA21004), once daily (QD), in Japanese participants with
      major depressive disorder.

      The purpose of this study is to assess the efficacy, safety and tolerability of 8-week
      treatment with Lu AA21004, once daily (QD), in Japanese participants with major depressive
      disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lu AA21004 was discovered by H. Lundbeck A/S, and is under co-development by H. Lundbeck A/S
      and Takeda for the treatment of major depressive disorder and general anxiety disorder. Major
      depressive disorder (MDD) is a chronic, recurring disease with considerable morbidity in the
      general population. The estimated lifetime prevalence of major depression in the adult
      population is 5 to 25%, with approximately 2-fold higher prevalence in women than in men. The
      hallmark of the disease is a depressed mood, with additional symptoms including sleep
      disturbances, psychomotor agitation or retardation, sexual dysfunction, weight loss,
      concentration difficulties and delusional ideas. In addition to direct ill effects, MDD
      causes suicide or job loss and exerts indirect influence on social economy. This study will
      assess the efficacy and the safety of Lu AA21004. This study consists of a 1-week screening
      period, an 8-week double-blind treatment period, 4-week safety follow-up.The duration of the
      study is 13 weeks in total. Blood samples will be collected from participants, and a safety
      follow-up contact (visit or phone call) will be made 4 weeks after completion of the 8-week
      double-blind treatment period. Subjects who complete the 8-week double-blind treatment period
      can successively enter a long-term extension study (Lu AA21004/OCT-001; NCT01395147;
      hereinafter, OCT-001), if they meet all inclusion criteria and none of exclusion criteria of
      the OCT-001 study and are willing to participate in the OCT-001 study. Subjects who will
      enter the OCT-001 will not be requested to safety follow-up after completion of the 8-week
      double-blind treatment period.

      Lu AA21004 was discovered by H. Lundbeck A/S, and is under co-development by H. Lundbeck A/S
      and Takeda for the treatment of major depressive disorder and general anxiety disorder.

      Major depressive disorder (MDD) is a chronic, recurring disease with considerable morbidity
      in the general population. The estimated lifetime prevalence of major depression in the adult
      population is 5 to 25%, with approximately 2-fold higher prevalence in women than in men. The
      hallmark of the disease is a depressed mood, with additional symptoms including sleep
      disturbances, psychomotor agitation or retardation, sexual dysfunction, weight loss,
      concentration difficulties and delusional ideas. In addition to direct ill effects, MDD
      causes suicide or job loss and exerts indirect influence on social economy.

      This study will assess the efficacy and the safety of Lu AA21004. This study consists of a
      1-week screening period, an 8-week double-blind treatment period, 4-week s safety
      follow-up.The duration of the study is 13 weeks in total. Blood samples will be collected
      from participants, and a safety follow-up contact (visit or phone call) will be made 4 weeks
      after completion of the 8-week double-blind treatment period.

      Subjects who complete the 8-week double-blind treatment period can successively enter a
      long-term extension study (Lu AA21004/OCT-001; NCT01395147; hereinafter, OCT-001), if they
      meet all inclusion criteria and none of exclusion criteria of the OCT-001 study and are
      willing to participate in the OCT-001 study.

      Subjects who will enter the OCT-001 will not be requested to safety follow-up after
      completion of the 8-week double-blind treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>MADRS is a 10-item clinician rated scale that measures overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates that symptoms have improved. An analysis of covariance (ANCOVA) model was used with change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With MADRS Response After 8 Weeks of Treatment</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Response is defined as a ≥50% decrease in the MADRS Total Score from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With MADRS Remission After 8 Weeks of Treatment</measure>
    <time_frame>Week 8</time_frame>
    <description>MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Remission is defined as a MADRS Total Score ≤10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The HAM-D17 is a 17-item rating scale that assesses depressed mood, agitation and somatic symptoms of depression, rated on a 5-point scale from 0 (absent) to 4 (very severe) with a total score range from 0 to 52. Higher scores indicate greater severity of depression symptoms. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the baseline HAM-D17 score as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The CGI-I assesses the clinician's impression of the participant's state of mental illness improvement and consists of one question for the investigator: &quot;Compared to his condition at the start of the study, how much has this patient changed?&quot; which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater severity of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms. ANCOVA model was used with treatment as a fixed effect and the baseline CGI-Severity (CGI-S) score as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the Baseline SDS total score as a covariate.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Vortioxetine 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Vortioxetine tablets</description>
    <arm_group_label>Vortioxetine 5 mg</arm_group_label>
    <arm_group_label>Vortioxetine 10 mg</arm_group_label>
    <other_name>Lu AA21004</other_name>
    <other_name>BRINTELLIX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vortioxetine placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vortioxetine placebo-matching tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject suffers from Major Depressive Disorder (MDD) as the primary diagnosis
             according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition,
             Text Revision (DSM-IV-TR) criteria (classification code 296.2x and 296.3x).

          2. The reported duration of the current major depressive episode is at least 3 months at
             the Screening Visit.

          3. The subject has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26 at
             the Screening and Baseline Visits.

          4. The subject has a Clinical Global Impression Scale-Severity (CGI-S) score ≥4 at the
             Screening and Baseline Visits

        Exclusion Criteria:

          1. The subject has one or more of the following conditions:

               -  Any current psychiatric disorder other than MDD as defined in the DSM-IV-TR. A
                  subject who exhibits symptoms of anxiety is eligible unless the subject fulfills
                  the diagnostic criteria for a current anxiety disorder per DSM-IV-TR.

               -  Current diagnosis or history of manic or hypomanic episode, schizophrenia or any
                  other psychotic disorder, including major depression with psychotic features,
                  mental retardation, organic mental disorders, or mental disorders due to a
                  general medical condition as defined in the DSM-IV-TR.

               -  Current diagnosis or history of any substance-related disorder (except nicotine
                  and caffeine-related disorders) as defined in the DSM-IV-TR.

               -  Presence or history of a clinically significant neurological disorder (including
                  epilepsy).

               -  Neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple
                  sclerosis, Huntington's disease, etc.).

               -  Any DSM-IV-TR axis II disorder that might compromise the study.

          2. The current depressive symptoms of the subject are considered by the investigator to
             have been resistant to 2 adequate antidepressant treatments of at least 6 weeks
             duration each.

          3. The subject is at significant risk of suicide or has a score ≥5 on Item 10 (suicidal
             thoughts) of the MADRS at the Screening and Baseline Visit, or has attempted suicide
             within 6 months prior to the Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Inzai-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Noda-City</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annaka-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujioka-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takasaki-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hatsukaichi-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-Shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amagasaki-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujisawa-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Kita-ku</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukaya-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama-city</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utsunomiya-shi</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anan-shi</city>
        <state>Tokushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushisma-shi</city>
        <state>Tokushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Musashino-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanyo-shi</city>
        <state>Yamagata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <results_first_submitted>November 4, 2014</results_first_submitted>
  <results_first_submitted_qc>November 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2014</results_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 32 investigative sites throughout Japan from 13 May 2011 to 21 December 2012.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of major depressive disorder were enrolled equally in 1 of 3 treatment groups: once a day 5 mg or 10 mg vortioxetine (Lu AA21004) or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vortioxetine 5 mg</title>
          <description>Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Vortioxetine 10 mg</title>
          <description>Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="123"/>
                <participants group_id="P3" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pretreatment Event or Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non Compliance with Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vortioxetine 5 mg</title>
          <description>Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Vortioxetine 10 mg</title>
          <description>Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="124"/>
            <count group_id="B4" value="366"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="10.85"/>
                    <measurement group_id="B2" value="38.8" spread="10.99"/>
                    <measurement group_id="B3" value="37.6" spread="10.67"/>
                    <measurement group_id="B4" value="38.4" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.7" spread="8.45"/>
                    <measurement group_id="B2" value="165.6" spread="8.51"/>
                    <measurement group_id="B3" value="163.9" spread="8.46"/>
                    <measurement group_id="B4" value="165.1" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.18" spread="11.357"/>
                    <measurement group_id="B2" value="62.11" spread="15.883"/>
                    <measurement group_id="B3" value="60.86" spread="12.690"/>
                    <measurement group_id="B4" value="61.71" spread="13.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.59" spread="3.366"/>
                    <measurement group_id="B2" value="22.42" spread="4.306"/>
                    <measurement group_id="B3" value="22.57" spread="4.016"/>
                    <measurement group_id="B4" value="22.53" spread="3.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cytochrome p450 (CYP)2D6 Phenotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ultra-rapid Metabolizer (UM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extensive Metabolizer (EM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate Metabolizer (IM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor Metabolizer (PM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Alcohol Consumption</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Once Monthly or Less Often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Once a Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 to 6 Times/Week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Status of Major Depressive Episode (MDE)</title>
          <description>An MDE is a period marked by depressed mood, loss of interest or pleasure, disturbed sleep or appetite, low energy, feelings of guilt or low self-worth, and poor concentration.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Single episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pharmacotherapy for Current Major Depressive Episode</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery Åsberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="4.81"/>
                    <measurement group_id="B2" value="32.5" spread="4.93"/>
                    <measurement group_id="B3" value="32.5" spread="4.50"/>
                    <measurement group_id="B4" value="32.4" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Depression Scale (HAM-D17) Total Score</title>
          <description>The HAM-D17 is a clinician-rated scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52 where a higher score indicates a greater depressive state.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.9" spread="4.12"/>
                    <measurement group_id="B2" value="21.2" spread="4.43"/>
                    <measurement group_id="B3" value="21.5" spread="4.48"/>
                    <measurement group_id="B4" value="21.2" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression - Severity Scale Score</title>
          <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="0.65"/>
                    <measurement group_id="B2" value="4.5" spread="0.64"/>
                    <measurement group_id="B3" value="4.6" spread="0.69"/>
                    <measurement group_id="B4" value="4.5" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sheehan Disability Scale (SDS) - Total Score</title>
          <description>The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.5" spread="6.12"/>
                    <measurement group_id="B2" value="15.2" spread="5.97"/>
                    <measurement group_id="B3" value="15.4" spread="5.45"/>
                    <measurement group_id="B4" value="15.4" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment</title>
        <description>MADRS is a 10-item clinician rated scale that measures overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates that symptoms have improved. An analysis of covariance (ANCOVA) model was used with change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug; who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 10 mg</title>
            <description>Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score After 8 Weeks of Treatment</title>
          <description>MADRS is a 10-item clinician rated scale that measures overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates that symptoms have improved. An analysis of covariance (ANCOVA) model was used with change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.</description>
          <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug; who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation. Last observation carried forward.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.84" spread="0.885"/>
                    <measurement group_id="O2" value="-14.85" spread="0.874"/>
                    <measurement group_id="O3" value="-13.81" spread="0.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1031</p_value>
            <method>ANCOVA</method>
            <method_desc>Change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.</method_desc>
            <param_type>Least square means difference</param_type>
            <param_value>-2.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.241</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.467</ci_lower_limit>
            <ci_upper_limit>0.413</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4008</p_value>
            <method>ANCOVA</method>
            <method_desc>Change in MADRS total score as a dependent variable, treatment as a fixed effect and the baseline MADRS total score as a covariate.</method_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>-1.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.233</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.461</ci_lower_limit>
            <ci_upper_limit>1.387</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With MADRS Response After 8 Weeks of Treatment</title>
        <description>MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Response is defined as a ≥50% decrease in the MADRS Total Score from Baseline.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug, who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 10 mg</title>
            <description>Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With MADRS Response After 8 Weeks of Treatment</title>
          <description>MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Response is defined as a ≥50% decrease in the MADRS Total Score from Baseline.</description>
          <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug, who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3"/>
                    <measurement group_id="O2" value="45.9"/>
                    <measurement group_id="O3" value="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With MADRS Remission After 8 Weeks of Treatment</title>
        <description>MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Remission is defined as a MADRS Total Score ≤10.</description>
        <time_frame>Week 8</time_frame>
        <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug, who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 10 mg</title>
            <description>Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With MADRS Remission After 8 Weeks of Treatment</title>
          <description>MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. Remission is defined as a MADRS Total Score ≤10.</description>
          <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug, who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4"/>
                    <measurement group_id="O2" value="28.7"/>
                    <measurement group_id="O3" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment</title>
        <description>The HAM-D17 is a 17-item rating scale that assesses depressed mood, agitation and somatic symptoms of depression, rated on a 5-point scale from 0 (absent) to 4 (very severe) with a total score range from 0 to 52. Higher scores indicate greater severity of depression symptoms. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the baseline HAM-D17 score as a covariate.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug, who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 10 mg</title>
            <description>Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Hamilton Depression Scale (HAM-D17) Total Score After 8 Weeks of Treatment</title>
          <description>The HAM-D17 is a 17-item rating scale that assesses depressed mood, agitation and somatic symptoms of depression, rated on a 5-point scale from 0 (absent) to 4 (very severe) with a total score range from 0 to 52. Higher scores indicate greater severity of depression symptoms. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the baseline HAM-D17 score as a covariate.</description>
          <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug, who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation. Last Observation Carried Forward.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.56" spread="0.586"/>
                    <measurement group_id="O2" value="-8.54" spread="0.580"/>
                    <measurement group_id="O3" value="-8.40" spread="0.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment</title>
        <description>The CGI-I assesses the clinician's impression of the participant's state of mental illness improvement and consists of one question for the investigator: &quot;Compared to his condition at the start of the study, how much has this patient changed?&quot; which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater severity of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms. ANCOVA model was used with treatment as a fixed effect and the baseline CGI-Severity (CGI-S) score as a covariate.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug, who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation. Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 10 mg</title>
            <description>Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression Scale-Improvement (CGI-I) Score After 8 Weeks of Treatment</title>
          <description>The CGI-I assesses the clinician's impression of the participant's state of mental illness improvement and consists of one question for the investigator: &quot;Compared to his condition at the start of the study, how much has this patient changed?&quot; which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater severity of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms. ANCOVA model was used with treatment as a fixed effect and the baseline CGI-Severity (CGI-S) score as a covariate.</description>
          <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug, who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation. Last Observation Carried Forward (LOCF).</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="0.100"/>
                    <measurement group_id="O2" value="2.57" spread="0.099"/>
                    <measurement group_id="O3" value="2.66" spread="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment</title>
        <description>The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the Baseline SDS total score as a covariate.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug, who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation. Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 10 mg</title>
            <description>Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sheehan Disability Scale (SDS) Total Score After 8 Weeks of Treatment</title>
          <description>The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment. A negative change from Baseline indicates that symptoms have improved. ANCOVA model was used with treatment as a fixed effect and the Baseline SDS total score as a covariate.</description>
          <population>Participants from the Full Analysis Set (FAS), defined as all participants who were randomized and received at least 1 dose of study drug, who had data available for this outcome measure. One participant in the Vortioxetine 10 mg group was excluded due to a major protocol deviation. Last Observation Carried Forward (LOCF).</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.01" spread="0.510"/>
                    <measurement group_id="O2" value="-4.02" spread="0.506"/>
                    <measurement group_id="O3" value="-2.91" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8-week double blind treatment period and 4-week follow-up safety period, or up to 4 weeks after withdrawal visit, excluding those who enrolled in the long-term extension study (Up to 12 Weeks)</time_frame>
      <desc>At each visit the investigator documented adverse events and abnormal laboratory findings reported by the patient or observed by the investigator irrespective of relation to study drug. Safety analysis set included all participants who received study drug. 1 participant in the Vortioxetine 10 mg group was excluded due to a major protocol violation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vortioxetine 5 mg</title>
          <description>Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Vortioxetine 10 mg</title>
          <description>Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pericoronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Self injurious behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

